Cimzia (Certolizumab Pegol) for Crohn's: A Patient Guide

If you or your gastroenterologist are weighing biologic options for moderate-to-severe Crohn's disease, certolizumab pegol (brand name Cimzia) deserves a close look - especially if pregnancy is part of your planning. Cimzia is an anti-TNF biologic that works differently from its better-known cousins like adalimumab and infliximab, and that structural difference shapes everything from how it crosses the placenta to how often you inject it. This guide walks through the evidence, the dosing, and the practical realities so you can hold a well-informed conversation with your care team.

Key Takeaways

• Certolizumab pegol is FDA-approved for moderately to severely active Crohn's disease in adults who have not responded adequately to conventional therapy (1)
• In the CRIB study, Cimzia was undetectable in 13 of 14 infants at birth, with only one infant showing a minimal level of 0.042 microgram per mL (3)
• In PRECiSE 2, 62% of patients who responded to induction maintained that response at week 26 on certolizumab pegol, compared to 34% on placebo (5)
• The PRECiSE 3 long-term extension followed 595 patients for up to 7 years, with clinical remission rates of at least 68% among those who remained on treatment (6)
• Cimzia is dosed every 4 weeks as a subcutaneous injection, and its unique PEGylated structure is what gives it a distinctive pregnancy and breastfeeding safety profile

What Is Cimzia and How Does It Work in Crohn's Disease?

Certolizumab pegol is a PEGylated Fab fragment of a humanized monoclonal antibody that neutralizes tumor necrosis factor-alpha (TNF-alpha), one of the key proteins driving intestinal inflammation in Crohn's disease. It was approved by the FDA in 2008 for reducing signs and symptoms of moderately to severely active Crohn's disease in adults who have not responded adequately to conventional therapy (1).

The Anti-TNF Mechanism in Crohn's Disease

Like other anti-TNF biologics, Cimzia works by binding to TNF-alpha and preventing it from triggering the inflammatory cascade that damages the intestinal lining. TNF-alpha acts as a chemical signal that recruits inflammatory cells to the gut wall - in Crohn's disease, this signal stays active even when there is no infection to fight. By capturing TNF-alpha before it can reach its receptors, certolizumab pegol helps turn down that overactive immune response. For a broader understanding of how this drug class works across different medications, see our overview of anti-TNF therapies in Crohn's disease.

Why Cimzia Is Structurally Different from Other Anti-TNFs

Here is where Cimzia stands apart from adalimumab (Humira) and infliximab (Remicade): it has no Fc region. Most antibody-based biologics are full-length antibodies with an Fc tail, which is the part that normally gets shuttled across the placenta by a specific receptor called FcRn. Cimzia uses only the antigen-binding fragment (Fab), attached to a polyethylene glycol (PEG) chain that extends the drug's half-life so it can be dosed every four weeks. This missing Fc region is not just a technical curiosity - it is the reason Cimzia has a fundamentally different pregnancy profile, which we cover in detail below. If you have been on adalimumab and are curious about the differences, this structural distinction is the most clinically meaningful one.

How Cimzia Is Dosed and Given

The dosing schedule for certolizumab pegol is straightforward once you understand the loading phase. All doses are given as subcutaneous injections - shots under the skin that you can learn to do at home after initial training.

The 400 mg Loading and Maintenance Schedule

The standard dosing regimen is (1, 8):

• Week 0: 400 mg subcutaneously (given as two separate 200 mg injections)
• Week 2: 400 mg subcutaneously (two 200 mg injections)
• Week 4: 400 mg subcutaneously (two 200 mg injections)
• Every 4 weeks thereafter: 400 mg (two 200 mg injections) for patients who achieve a clinical response

Before starting Cimzia, your care team will run a few screening tests, including a tuberculosis test (PPD skin test or IGRA blood test), hepatitis B screening, and a review of your vaccination history. These precautions apply to all anti-TNF biologics, not just certolizumab pegol.

Self-Injection at Home

Cimzia is available as a prefilled syringe that patients can use at home after proper training, or as a lyophilized powder that gets reconstituted and administered in a clinical setting. Most patients use the prefilled syringe. Each 400 mg dose requires two separate 200 mg injections, typically given in the abdomen or thigh. Rotate your injection site each time. If you experience anxiety around needles, our guide on managing needle anxiety with biologic injections covers practical strategies that many in our community have found helpful.

What the Evidence Says About Efficacy

Certolizumab pegol's evidence base rests primarily on the PRECiSE clinical trial program - a series of large, well-designed studies that tested the drug across different stages of treatment.

The PRECiSE Clinical Trial Program

PRECiSE 1 enrolled 662 patients with moderate to severe Crohn's disease and tested certolizumab pegol against placebo over 26 weeks. Among patients with elevated C-reactive protein (CRP) at baseline, the response rate was 22% for certolizumab pegol versus 12% for placebo (7). This trial established that the drug could induce a meaningful clinical response.

PRECiSE 2 focused on what happens after induction and is one of the most important maintenance studies for this drug. Among patients who responded during the initial dosing phase, 62% maintained that response at week 26 on certolizumab pegol compared to just 34% on placebo (5). These results demonstrated that continuing treatment preserves the benefit - a critical point for a disease as relapse-prone as Crohn's.

PRECiSE 3, the open-label long-term extension, followed 595 patients for up to 7 years. Among those who remained on treatment (observed cases), clinical remission rates were at least 68% at each annual assessment (6). Long-term data like this matters because Crohn's is a lifelong condition, and patients need to know whether a drug holds up over years, not just months.

PRECiSE 4 showed that patients who lost response and then received reinduction dosing could regain remission in a substantial proportion of cases - reassuring evidence that a temporary setback does not necessarily mean the drug has stopped working for good.

How Cimzia Compares to Other Crohn's Biologics

Head-to-head trials comparing certolizumab pegol directly against other biologics in Crohn's disease are limited, so most comparisons rely on indirect evidence. Cimzia occupies the same anti-TNF class as adalimumab and infliximab, and its overall efficacy profile is broadly similar. Where it stands out is in its pregnancy and breastfeeding data (covered below) and its every-4-week dosing schedule. Your gastroenterologist will weigh these practical factors alongside your disease severity, prior treatment history, and personal circumstances when recommending the best option for you.

The Cimzia Pregnancy and Breastfeeding Profile

This is the section that sets Cimzia apart from every other anti-TNF, and it is the reason many gastroenterologists specifically choose certolizumab pegol for patients who are pregnant or planning to become pregnant. For broader context on managing Crohn's during pregnancy, see our comprehensive pregnancy management guide.

The CRIB Study on Placental Transfer

Because certolizumab pegol lacks the Fc region that normally shuttles antibodies across the placenta, researchers hypothesized that it would transfer to the fetus at much lower levels than other anti-TNFs. The CRIB study (Mariette et al., Annals of the Rheumatic Diseases 2018) confirmed this: infant blood samples taken at birth showed no detectable certolizumab pegol in 13 of 14 infants. The one infant with a detectable level showed just 0.042 microgram per mL - a minimal amount (3). For comparison, infliximab and adalimumab are routinely detected at therapeutic or near-therapeutic levels in newborn blood.

The CRADLE Study on Breast Milk

The CRADLE study measured certolizumab pegol levels in the breast milk of 17 lactating patients and found that levels were very low or undetectable. The estimated relative infant dose fell well below the 10% threshold that is generally considered acceptable for medication exposure through breast milk (4). This gives many nursing parents and their doctors confidence that breastfeeding can continue during treatment.

What Guidelines Now Recommend

The cumulative safety data is substantial. MotherToBaby reports more than 2,000 published pregnancy exposures to certolizumab pegol with no signal for increased birth defects or miscarriage above the general-population baseline (4). The 2024 EULAR recommendations and the current US prescribing information both support continuing certolizumab pegol throughout pregnancy when clinically needed, and consider it compatible with breastfeeding (1). This does not mean other anti-TNFs are unsafe in pregnancy - they are used regularly with good outcomes - but Cimzia's data on minimal placental transfer is uniquely reassuring for patients and providers who want the lowest possible fetal drug exposure.

Safety, Side Effects, and What to Watch For

Like all anti-TNF biologics, certolizumab pegol modifies immune function, and that comes with trade-offs. Understanding the safety profile helps you monitor yourself and communicate effectively with your care team.

Infection Risk and Vaccination

Cimzia carries a boxed warning for serious infections, including tuberculosis, invasive fungal infections, and bacterial sepsis. This is a class-wide warning shared by all anti-TNF biologics, not unique to certolizumab pegol. In practice, most patients tolerate the drug well, but you should be vigilant about any signs of infection - persistent fever, unusual cough, night sweats, or wounds that will not heal. Live vaccines (such as the live shingles vaccine or MMR) should be avoided while you are on Cimzia. Inactivated vaccines, including flu shots and COVID boosters, are safe and recommended during treatment.

Serious Warnings on the FDA Label

In addition to infection risk, the FDA label includes warnings about malignancies, including lymphoma, and about new or worsening heart failure. These risks are associated with the entire anti-TNF class and were identified across all anti-TNF drugs, not from certolizumab-specific signals. Rare cases of demyelinating disease and lupus-like reactions have also been reported. While these serious events are uncommon, they are worth knowing about so you can report any unusual neurological symptoms or new joint pain to your doctor promptly (1).

Common Day-to-Day Side Effects

The most frequently reported side effects in Crohn's clinical trials included upper respiratory tract infections, rash, and urinary tract infections. Injection site reactions can occur but are typically milder than with some other subcutaneous biologics - many patients note that Cimzia does not sting as much on injection. If you develop any persistent or bothersome side effects, talk to your gastroenterologist before making any changes to your treatment.

Practical Questions Patients Ask

Beyond the clinical trial data, living with a biologic means navigating real-world logistics. Here are the answers to the questions our community raises most often about Cimzia.

How Quickly Does Cimzia Work?

Many patients begin noticing symptom improvement within the first weeks after the loading doses at weeks 0, 2, and 4. However, the full benefit of the drug may not be apparent until around week 26 - this is the timepoint used in the pivotal PRECiSE trials. If you are feeling discouraged after a few weeks, it is worth discussing with your GI team whether to give the drug more time, especially if your inflammatory markers are trending in the right direction.

What Happens if I Miss a Dose?

If you miss a scheduled dose, the general advice is to take it as soon as you remember and then resume your regular every-4-week schedule from that point. Missing a single dose does not necessarily mean you will lose your response, but consistent dosing gives you the best chance of staying in remission. If you have missed multiple doses, contact your gastroenterologist for guidance on whether reinduction is needed.

Coverage, Cost, and Patient Support

Cimzia, like all brand-name biologics, can be expensive. UCB (the manufacturer) runs the UCBCares patient support program, which can help with insurance prior authorization, copay assistance cards, and injection training. If you are struggling with coverage, ask your GI team's office to connect you with UCBCares - they deal with insurance obstacles regularly and often know the fastest routes through the process. Looking ahead, certolizumab pegol will lose US patent protection later this decade, and biosimilars are already approved in some European markets. This is expected to bring cost down over time, similar to what has happened with adalimumab biosimilars.

Frequently Asked Questions

Is Cimzia safe to take during pregnancy?

Current evidence strongly supports the safety of certolizumab pegol during pregnancy. The CRIB study found minimal to no placental transfer, and more than 2,000 published pregnancy exposures show no increased risk of birth defects or miscarriage (3, 4). Both EULAR guidelines and the US prescribing label support continuing the drug throughout pregnancy when clinically needed. However, all treatment decisions during pregnancy should be made together with your gastroenterologist and obstetrician.

How is Cimzia different from Humira or Remicade?

All three are anti-TNF biologics, but Cimzia is structurally unique because it uses only the antigen-binding fragment of an antibody (the Fab) rather than the full antibody molecule. It lacks the Fc region, which is the part that gets actively transported across the placenta. This gives Cimzia its distinctive low placental transfer profile. Cimzia is also PEGylated, which extends its half-life and allows every-4-week dosing as a subcutaneous injection (1).

How long does Cimzia take to start working?

Many patients notice improvement in symptoms within the first few weeks after the three loading doses (given at weeks 0, 2, and 4). Maximum clinical benefit is typically observed by week 26 in clinical trials (5). If your symptoms are not improving after several weeks, your gastroenterologist may check inflammatory markers like CRP or calprotectin to assess whether the drug is working at a biological level.

Can I breastfeed while taking Cimzia?

The CRADLE study measured certolizumab pegol in breast milk and found levels that were very low or undetectable, with an estimated relative infant dose well below the accepted 10% threshold (4). Current guidelines and the US prescribing label consider Cimzia compatible with breastfeeding. Discuss your specific situation with your healthcare team, but the data is reassuring.

What should I do if Cimzia stops working?

Loss of response can happen with any biologic. If your symptoms return, your gastroenterologist may check drug levels and anti-drug antibodies to understand why. Options include dose optimization, switching to a different anti-TNF, or moving to a biologic with a different mechanism of action such as ustekinumab or risankizumab. The PRECiSE 4 study showed that reinduction after disease flare can restore response in many patients, so losing response does not always mean the drug is finished for you.

Does Cimzia increase cancer risk?

The FDA label for all anti-TNF biologics, including Cimzia, carries a boxed warning about malignancies, including lymphoma. This is a class-wide precaution. In practice, the absolute risk increase is very small, and the risk of undertreated Crohn's disease - including the inflammation-driven risk of colorectal cancer - is also a serious consideration. Your gastroenterologist can help you weigh these risks in the context of your specific disease severity and treatment alternatives (1).

Will biosimilars make Cimzia more affordable?

Biosimilars for certolizumab pegol are already approved in some European markets, and US patent expiration is expected later this decade. When biosimilars become widely available, they typically bring meaningful cost reductions - as seen with adalimumab biosimilars. In the meantime, the UCBCares patient support program offers copay assistance and can help with insurance challenges. Coverage and costs vary by country and insurance plan, so check with your local healthcare system for specifics.

References

1. US Food and Drug Administration. CIMZIA (certolizumab pegol) Prescribing Information. 2024. Read prescribing information
2. MotherToBaby. Certolizumab Pegol (Cimzia) Fact Sheet. 2024. Read fact sheet
3. Mariette X, Forger F, Abraham B, et al. Lack of placental transfer of certolizumab pegol during pregnancy: results from CRIB, a prospective, postmarketing, pharmacokinetic study. Annals of the Rheumatic Diseases 2018; 77:228-233. Read study on PubMed
4. MotherToBaby. Certolizumab Pegol (Cimzia) - NCBI Bookshelf. 2024. Read on NCBI
5. Schreiber S, Khaliq-Kareemi M, Lawrance IC, et al. Maintenance Therapy with Certolizumab Pegol for Crohn's Disease. New England Journal of Medicine 2007; 357:239-250. Read study in NEJM
6. Sandborn WJ, Lee SD, Randall C, et al. Long-term safety and efficacy of certolizumab pegol in the treatment of Crohn's disease: 7-year results from the PRECiSE 3 study. Alimentary Pharmacology and Therapeutics 2014. Read study on PubMed
7. Sandborn WJ, Feagan BG, Stoinov S, et al. Certolizumab Pegol for the Treatment of Crohn's Disease. New England Journal of Medicine 2007; 357:228-238. Read study in NEJM
8. UCB. CIMZIA Dosing for Crohn's Disease. 2025. Read dosing information